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OBJECTIVE: Evaluate earnings associated with early,
late, or any stages of ARM, a progressive vision-compro-
mising condition, compared to a general elderly cohort.
METHODS: Earnings of an ARM population 65 years
and a general cohort 65 years were retrospectively eval-
uated to estimate potential earnings differences. ARM
prevalence data were obtained from prospective land-
mark studies in the US, Australia, and The Netherlands.
Prevalence data and census data, were used to estimate
the number of ARM patients in these countries. Beaver
Dam (BD) study income data were used to calculate the
median income for each stage of ARM. US Social Secu-
rity (SS) median income data for the general cohort pop-
ulation 65 was calculated using identical BD income
categories. BD income was adjusted for inflation and re-
gional differences. By multiplying the estimated number
of patients per given country within each specified earn-
ings category of ARM by respective median incomes, an-
nual societal earnings were calculated. Likewise, multi-
plying the number of elderly without ARM by the SS
median annual income produced an income estimate of
persons without ARM. RESULTS: Estimated BD in-
comes for persons with ARM 65 years were $27,000,
$21,000 and $27,000 for the early, late, and any groups,
respectively. The income for the general population 65
was estimated at $31,000. The early ARM group has
higher earnings related to the higher prevalence of this
cohort, and possibly higher per capita income in what is
likely to be a younger sub-population. Total estimated
earnings for the any ARM group were $240 billion. By
comparison, the total income for “no” ARM was $803
billion. ARM patients are 26% of the 65 years popula-
tion but earn only 23% of this group’s income. This pat-
tern was repeated across five studies. CONCLUSION:
The wage impact associated with ARM appears large and
represents a significant indirect societal cost of AMD.
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OBJECTIVE: To define actual practice patterns for glau-
coma and estimate the resources utilization, total cost of
treatment and costs distribution in patients categorised
into groups according to type of glaucoma and then
stratified according to stage of illness. METHODS: The
observational study included 193 patients with open-angle
(OAG) and 122 patients with closed-angle glaucoma
(CAG) recruited by ophthalmologist in Mazowian Re-
gional Centre of Glaucoma Diagnosis and Treatment. Pa-
tients were categorised into OAG and CAG groups and
then stratified according to intraocular pressure (16
mmHg-I, 17–22 mmHg-II, 22 mmHg-III) or changes in
C/D (C/D0,5-a, C/D0,6-b). Number of eyes in exam-
ined subgroups were: OAG I-154, II-165, III-45, 1–124,
2–240; CAG I-113, II-74, III-40, 1–114, 2–113, respec-
tively. The perspective of health-care payers and time ho-
rizon 18 months were taken. Quantities of resources or
services used and their costs were collected separately,
and then quantities multiplied by the price. Costs were
summarized for the main resource categories (pharma-
ceuticals, outpatient consultations, surgery, laser ther-
apy). Resources used and costs in each group were calcu-
lated per 100eyes/1year, what permitted a cross-group
comparison. RESULTS: The total cost of glaucoma treat-
ment was highest in CAG-III (108032 PLN/100eyes/1year,
1 USD  4,5 PLN) and OAG-III or b (99400 PLN/
100eyes/1year). The major cost driver in CAG-a and
OAG-b was surgery (36% of total costs), in all other,
mostly in stage III, were pharmaceuticals: in OAG-III and
CAG-III–50%, in OAG-b – 40% of total costs. In OAG-2
and CAG-b, CAG-I and CAG-II 30% of total costs arose
from surgery. The most frequent used pharmaceuticals
were: in OAG–timolol, in CAG–pilocarpine. The third–
dorzolamid-was used in OAG nad CAG, most frequent
in stage III. CONCLUSION: The total cost of glaucoma
treatment and costs distribution depends on the severity
of illness. Beyond CAG-a and OAG-b group, the most
expensive was pharmacological treatment.
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OBJECTIVE: To compare costs and effects of continuous
terbinafine and intermittent itraconazole in the treatment of
toenail onychomycosis in Poland. This was intended to
facilitate the decision-making process in selecting the more
cost-effective treatment for toenail onychomycosis. METH-
ODS: L.I.O.N. study results were used to estimate effec-
tiveness of terbinafine 0,25 g/d for 12 or 16 weeks (T12,
T16) and itraconazole 0,4 g/d for 1 week in every 4 weeks
for 12 or 16 weeks (I3, I4). The measure of treatment ef-
fectiveness was complete cure and average number of dis-
ease-free days per patient. Direct medical costs were esti-
mated on the basis of current treatment patterns in Poland.
The perspective of health care payers and time horizon of
72 weeks were taken. The decision model was used to
quantify cost and effectiveness of alternative treatments.
One-way, two-way sensitivity analysis and treshold anal-
ysis were performed. RESULTS: Cost/patient cured and
cost/disease-free day were (in PLN, 1 USD  4,5 PLN)):
for T12 - 2199 and 10,6 for T16 - 2279 and 10,6, for I3 -
4207 and 16,9, for I4 - 4670 and 20,3. Incremental anal-
ysis suggests, that I3 and I4 are dominated programs,
